
Floortje van Nooten
Health Economist and Head of Market Access, Shionogi Europe

Merel Gijsen
Antimicrobial Market Access Lead, Shionogi Europe
A different economic approach is needed to ensure we are protecting the effectiveness and development of available antimicrobials. Antibiotics must be valued differently from other medicines.
Antimicrobial resistance (AMR) is a major public health concern, with bacterial AMR directly responsible for over 1.14 million deaths worldwide each year.1 This figure, however, underestimates the wider societal impact, including the impact on patients whose treatment and outcomes depend on effective infection prevention.
“Many of the treatments we take for granted today, including routine surgeries and transplants, simply wouldn’t be possible without antibiotics,” explains Floortje van Nooten, Health Economist and Head of Market Access, Shionogi Europe, a global pharmaceutical company. “This is particularly important in cancer care, where patients may rely on effective antibiotics to safely undergo life-saving treatments such as chemotherapy. After all, what is the value of investing in innovative cancer therapies if patients remain at risk of dying from a drug-resistant infection? Antibiotics don’t just save lives in their own right; they also help make other treatments possible. Unfortunately, this wider societal contribution isn’t necessarily reflected in how they are valued.”
The challenge of traditional antibiotic sales models
To preserve their effectiveness, antibiotics must be used responsibly in line with antimicrobial stewardship, a healthcare-wide approach to promote and monitor the use of antimicrobials, preserving their future effectiveness. In the context of sales-based models based on volume, this can make their development commercially challenging. Despite the rising deaths caused by resistant infections, research into new antibiotics has dropped by 35% in the last five years.2
There needs to be a balance between encouraging innovation and protecting the effectiveness of existing treatments. “We shouldn’t be promoting the sale of antibiotics Subscription models reward availability, not volume when responsible use means limiting how often they are prescribed,” adds Merel Gijsen, EU Antimicrobial Market Access Lead. “The antibiotics with the greatest value are those that are rarely used.”
If there is no incentive to continue research to find new antibiotics, the consequences will extend beyond rising AMR
“The traditional pharmaceutical The UK’s world-first pilot Antimicrobial Products Subscription Model, as well as approaches in France, Italy, Sweden and Japan, offer examples of how the right economic framework can support and reward availability and access rather than relying primarily on sales volumes. If there is no incentive to continue research to find new antibiotics, the consequences will extend beyond rising AMR. business model is based on volume, meaning the more products they sell, the more money they make,” explains van Nooten. “That model simply doesn’t work for antibiotics.” “The UK pilot subscription model means companies are paid for making an antibiotic available, with volume separated from payments received,” explains van Nooten. “This gives healthcare systems the flexibility to use these products responsibly while providing companies with greater certainty around the return on their investment.” Antibiotics’
The risk of continued underinvestment
If there is no incentive to continue research to find new antibiotics, the consequences will extend beyond rising AMR, to the potential loss of our ability to deliver many of the treatments we now take for granted. “This continued underinvestment significantly undermines medical progress across multiple therapeutic areas,” explains van Nooten. “Antibiotics are a cornerstone of modern medicine, but governments don’t always recognise how often they actually save lives.”
“Antibiotics take a long time to develop, and the evidence generated in clinical trials doesn’t always translate easily into how authorities assess their value,” adds Gijsen. “We need to look at antibiotic value differently, considering the benefits they bring beyond what traditional clinical evidence captures, or we will be left without the tools needed to protect patients and sustain modern medicine.”
Subscription models reward availability, not volume
The UK’s world-first pilot Antimicrobial Products Subscription Model, as well as approaches in France, Italy, Sweden and Japan, offer examples of how the right economic framework can support and reward availability and access rather than relying primarily on sales volumes.
“The UK pilot subscription model means companies are paid for making an antibiotic available, with volume separated from payments received,” explains van Nooten. “This gives healthcare systems the flexibility to use these products responsibly while providing companies with greater certainty around the return on their investment
Antibiotics’ wider value must shape economic decisions
A lack of effective antibiotics will have significant consequences, and while different countries have adopted different approaches, such incentives demonstrate how their wider value can be incorporated into economic decisions. The defining point is clear, as van Nooten explains: “Governments must adapt their thinking on how to value antibiotics, working collaboratively with the pharmaceutical industry to establish sustainable incentives for antimicrobial innovation to encourage more research into the antibiotics we vitally need for the future.”
[1] Naghavi M, Vollset S, Ikuta K et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, 2024; 404, 1199-1226.
[2] Mahase, Elisabeth. Antimicrobial Resistance: Pharma Pipeline Projects Drop by over a Third. BMJ, vol. 392, 12 Mar. 2026, article s479, https://doi.org/10.1136/ bmj.s479
NP-EU-NP-0393, November 2026
Global Cause